drugset / Trial / NCT05069220
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
NaSingle-groupOpen-labelDiagnostic
Summary
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and paraganglioma (PPGL) and neuroblastoma (NB).
Timeline
- Start
- 2021-09-01
- Primary completion
- 2025-09
- Completion
- 2026-12
Publications
- Wang P, Yu S, Chen X, Zheng X, Mao J, Jing H, Zhuang H, Li F, Su X. [18F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET. Eur J Nucl Med Mol Imaging. 2026 Jan;53(2):899-909. doi: 10.1007/s00259-025-07449-y. Epub 2025 Jul 28.
- Wang P, Li T, Liu Z, Jin M, Su Y, Zhang J, Jing H, Zhuang H, Li F. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma. Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3097-3106. doi: 10.1007/s00259-023-06221-4. Epub 2023 May 9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-DOTATATE | Diagnostic / imaging agent | — | Intravenous |
| Subject | M-FLUOROBENZYLGUANIDINE | Diagnostic / imaging agent | 2 mbq/kg | Intravenous |
| Subject | M-FLUOROBENZYLGUANIDINE | Diagnostic / imaging agent | 4 mbq/kg | Intravenous |